ICOS Corporation to Release 2003 Financial Results on February 3, 2004.Business Editors & Health/Medical Writers BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 19, 2004 ICOS Corporation (Nasdaq:ICOS) will announce its 2003 full year and fourth quarter financial results on February 3, 2004, after the market close. Following the announcement, company management will host a webcast discussion of financial results and related matters at 4:30 p.m. EST. ICOS will also provide financial guidance and discuss plans for 2004. Access to the discussion can be obtained as follows. LIVE Access on February 3, 2004, 4:30 p.m. EST: -- Phone (612) 326-1003; Passcode 715988. -- Webcast connection through the ICOS website at www.icos.com in the Investor/Events section. REPLAY Access: -- Phone replay accessible from February 3, 2004, 8:30 p.m. EST for 24 hours Adv. 1. for 24 hours - without stopping; "she worked around the clock" around the clock, round the clock at (320) 365-3844; Passcode 715988. -- Webcast replay, available through January 10, 2004, on ICOS' website at www.icos.com in the Investor/Events section. Additional information on ICOS, including past press releases, is also available at www.icos.com. About ICOS Corporation: ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology Structural biology is a branch of molecular biology concerned with the study of the architecture and shape of biological macromolecules—proteins and nucleic acids in particular—and what causes them to have the structures they have. , high throughput drug screening, medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. and gene expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. and other urologic disorders urologic disorder Any condition affecting the kidneys, often understood to be of the collecting tubules and southward. Cf Kidney disease. , and inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing opportunities to market breakthrough products. The forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. contained in this press release represent ICOS' judgment as of the date of this release. ICOS undertakes no obligation to publicly update any forward-looking statements. The biotechnology and pharmaceutical businesses are risky and there can be no assurance that any particular product candidate will progress and become a commercial product. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion